It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The phospholipid biosynthesis of the malaria parasite, Plasmodium falciparum is a key process for its survival and its inhibition is a validated antimalarial therapeutic approach. The second and rate-limiting step of the de novo phosphatidylcholine biosynthesis is catalysed by CTP: phosphocholine cytidylyltransferase (PfCCT), which has a key regulatory function within the pathway. Here, we investigate the functional impact of the key structural differences and their respective role in the structurally unique pseudo-heterodimer PfCCT protein in a heterologous cellular context using the thermosensitive CCT-mutant CHO-MT58 cell line. We found that a Plasmodium-specific lysine-rich insertion within the catalytic domain of PfCCT acts as a nuclear localization signal and its deletion decreases the nuclear propensity of the protein in the model cell line. We further showed that the putative membrane-binding domain also affected the nuclear localization of the protein. Moreover, activation of phosphatidylcholine biosynthesis by phospholipase C treatment induces the partial nuclear-to-cytoplasmic translocation of PfCCT. We additionally investigated the cellular function of several PfCCT truncated constructs in a CHO-MT58 based rescue assay. In absence of the endogenous CCT activity we observed that truncated constructs lacking the lysine-rich insertion, or the membrane-binding domain provided similar cell survival ratio as the full length PfCCT protein.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Research Centre for Natural Sciences, Institute of Enzymology, Budapest, Hungary (GRID:grid.425578.9) (ISNI:0000 0004 0512 3755); University of Szeged, Doctoral School of Multidisciplinary Medical Sciences, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625); Budapest University of Technology and Economics, Department of Applied Biotechnology, Budapest, Hungary (GRID:grid.6759.d) (ISNI:0000 0001 2180 0451)
2 Research Centre for Natural Sciences, Institute of Enzymology, Budapest, Hungary (GRID:grid.425578.9) (ISNI:0000 0004 0512 3755)
3 Research Centre for Natural Sciences, Institute of Enzymology, Budapest, Hungary (GRID:grid.425578.9) (ISNI:0000 0004 0512 3755); Budapest University of Technology and Economics, Department of Applied Biotechnology, Budapest, Hungary (GRID:grid.6759.d) (ISNI:0000 0001 2180 0451); University of Oxford, Division of Structural Biology, Wellcome Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 Research Centre for Natural Sciences, Institute of Enzymology, Budapest, Hungary (GRID:grid.425578.9) (ISNI:0000 0004 0512 3755); Budapest University of Technology and Economics, Department of Applied Biotechnology, Budapest, Hungary (GRID:grid.6759.d) (ISNI:0000 0001 2180 0451)